1. The document provides an agenda and overview for VioVi, an Italian juice company focused on blood orange juice. 2. It discusses VioVi's history, acquisition of an Italian production plant, product portfolio including juice, concentrates and essential oils, and management team. 3. Financial projections show revenues growing from €6.9 million in 2009 to €22.2 million in 2013, with the company reaching break even in 2010 and net profits of over €4 million by 2013.

2. Agenda
1. How we create value
2. Company Overview
3. History
4. 4 Year Projections
Feedback: Giuseppe Mascarella
giuseppe@viovijuice.com
Cell: +1 425 269 5478
CONFIDENTIAL
CONFIDENTIAL
13/01/2008 2

3. VioVi Adds Value In The Value Chain
Commodity Commodity Private
+ $ 1,75
Juice & Italian Brand Juice per Kg
Label MIX
Juices MIX MIX Juice
0.75 $/Kg 1.35 €/Kg ( + 0,40) 1.80 $/Kg(+ 0,50 ) 2.50 $/Kg (+ 0,70 )
€ 1.50 € 1.50
Market Price
€ 1.20
€ 1.00 € 0.90
€ 0.50
€ 0.50
€-
Brasilian Brasilian & Private
Juice Brand
Italian Label Mix Juice Mix
Juice

4. Tasty
Healthy Exotic
VioVi’ is a premuim brand
targeting baby boomers
leveraging the delicious and
health vitalizing juice from
Italian Blood Oranges.

5. VioVi
1. Brands in Antioxidant Drinks Are Hot
Pepsi just bought AmaCoco, Coke responded with with
ZiCO (Coco Water) to gain control over exotic healthy
beverages.
2. Market Momentum
Blood Oranges ranked #1 novelty trend by IFT (USA)
3. Unique Benefits
Over 50 scientific publications
4. Expertise
Italian manufacturing plant has been producing private
labels for over 10 years.
CONFIDENTIAL

6. VioVi Potential in USA/Canada
Proven in Italy and France where Blood Orange Juice has been one of the best seller for years.
Category : Healthy Foods in US Growth of Color Heathy Foods (including Juice)
will be $150 bil in 2012 Rev $ bn
Beverages Part Growing faster
than food at 30% /yr 600
500
400
300
200
100
Blood Orange 0
2002 2003 2004 2005 2006 2007
Juice in US is up
Rev $ bn 309.4452 336.3535 369.6192 410.688 446.4 480
400% in 2009
Source: Ewa Hudson EUROMONITOR Research

7. Addressable market in USA for the:
Consumer Taste
1990 2000 2005 2010
Sweet TART
$0.5Bil 2008 Market
Growth: 9%
$3Bil
Easy Orange Juice
Upgrade
Market: $1Bil
CONFIDENTIAL

8. Health Benefits of Blood Orange Juice
Based on Publications
PROMOTES CARDIOVASCULAR HEALTH
Flavonoids from Blood Orange juice
300% more
can prevent heart attacks and strokes. Antioxidants
GOOD ENERGY SOURCE
A research study found an accelerated recovery
experienced by professional handball players (Bonina et
al. 2005).
SUPPORTS BRAIN FUNCTIONS
It slows down the damaging effects of aging on
nerve cell function and supports a bright mood.
HEALTHIER SKIN
A study shows that BOJ support reversing the signs
of aging due to UV (Sun). (Proteggente 2003)
CONFIDENTIAL

9. Agenda
1. How we create value
2. Company Overview
3. History
4. 4 Year Projections
Feedback: Giuseppe Mascarella
giuseppe@viovijuice.com
Cell: +1 425 269 5478
13/01/2008 CONFIDENTIAL 9

10. Capitalizing the on the profit opportunity
with the antioxidant Blood Oranges
A. VioVi, Premium Healthy Brand
In USA/Canada with great marketing.
B. Largest Juice production & copacking plant in Italy
CONFIDENTIAL 10

11. A) VioVI Sales and Marketing USA
US National Sales Management (3)
US Regional Sales Managers (16)
Canadian Sales Manger (1)
Hotel and Restaurants
Piggy Back on Upper Scale Dessert Channel
CONFIDENTIAL

12. B) Overview of The Italian Production Plant
1. Largest Blood Orange Juice plant
– 93,527 sq m of manufacturing park (50% covered)
– 9000 unit/hr packing technology by Elopack
– 90,000 MT/Year production capacity
2. Ample Supply of Fruit: Over 3000 farmers are partners. Tot. market value 260
mil/year
3. Experience: 60 employees trained by Parmalt Enginnering
4. Certifications: USDA Organic, EU Biologic, Kosher, COKE certified, etc
5. Innovative: Scientific Advisory Board with over 50 scientists
worldwide collaborating in protected web
CONFIDENTIAL 12

13. Cold Store
CONFIDENTIAL

14. Products
From Sicilian Blood oranges, Blond Oranges, Lemons,
Grapefruit we produce:
• Juice
• Juice Concentrate , Cloudy, Comminuted
• Italian Soda Syrups, ICE Cream Base
• Orange Pulp
• Essential Oil for perfume, flavoring
• Oil and Water Phase for cosmetics
• Orange Peel Dried (Food and Heating)
• Prebiotic
• D-Limonene
CONFIDENTIAL

15. Talented Management
CONFIDENTIAL- CIPRO GEST BUSINESS PLAN 2008
Giuseppe Mascarella (73%)
President of O’Biolla and VioVi
Resident Seattle(USA). He is leading the conversion of a $38
million mature technologplant (formerly owned by Parmalat),
into a larger innovative biotech company specializing in
“nutraceuticals.
Before coming to O’Biolla, Giuseppe was a Group Manager at
Microsoft Corporation, driving the historical success of
Microsoft Office.. He firmly believes he can replicate that
success with the launch of the new O'Biolla product
He holds a master in Manufacturing Engineering, MBA from
MIT and JCU.
Fabio Borsellino (18%) Alessandro Rampolla (9%)
CEO of CiproGest. Living in Palermo Italy HR Executive Consultant
Alessandro Rampolla, has been production plant
He has worked as Strategy Consulting Manager for
manager for Procter & Gambles .
few a leading American Corporations such as Ernest Today he leads the Human Resources division in
and Young, ATHOS, Gartner Group, for 14 years. Brussels.
He holds a Master in Production Engineering.
Fabio Borsellino holds a Bocconi MBA and a Master
in Electrical Engineering.
• Pagina 15

16. ORANGE/LEMON PRODUCTION In Sicily
2008-09 FORECAST
Tot. Italian Orange Production over 2 mil Tons
Tot. Sicil Lemon Production over 5 mil Tons
Source: ISMEA (Government)
Cipro Gest
132.000 T
130.000 T
Reggio Calabria 525.000 T
300.000 T
115.600 T
253.000 T
92.000 T 92.000 T
3.000 T CONFIDENTIAL
13/01/2008 16

17. Agenda
1. How we create value
2. Company Overview
3. History
4. 4 Year Projections
Feedback: Giuseppe Mascarella
giuseppe@viovijuice.com
Cell: +1 425 269 5478
CONFIDENTIAL
CONFIDENTIAL
13/01/2008 17

18. VioVi Plant (Cipro Gest Srl, Italy)
HISTORICAL VIEW 2007-2009
 July 2007 – Acquisition of Plant from Parmalat Bankruptcy
 July 2007/2010 - One Time Re-Start Maintenance
 Jan 2008 – Juice Production with € 7 Mil production
 2008 – Biotechnologies R&D
 2009 – Private Label

19. R EVEN U ES FY2009 YT D
FY 2007 % FY 2008 % % %
(Amounts in thousands of euros) (Projection) 06.09
Revenues from PRIVATE LABEL MIX 0 0.00% 0 0.00% 893 12.90% 11 0.47%
Revenues from JUICE IN DRUMS 33 9.47% 3,856 60.71% 5,977 86.38% 3,336 141.79%
Revenues from D-LIMONENE & ESSENTIAL OILS 0 0.00% 406 6.39% 50 0.72% 15 0.64%
N e t R e v e nue s 33 9.47% 4,261 67.10% 6,919 100.00% 3,362 142.89%
Inventory Variation 315 90.53% 2,089 32.90% 0 0.00% -1,009 -42.89%
VALU E OF PR OD U CT ION 348 100.00% 6,351 100.00% 6,919 100.00% 2,353 100.00%
Value of Production 2007-2009
Net Revenues Inventory Variation
8,000
7,000
6,000
Thousands of Euros
2,089
5,000
4,000
6,919
3,000
2,000 4,261
1,000
33
0
FY 2007 FY 2008 FY2009 (Projection)

20. 2008-2009 INCOME STATEMENTS
INCOME STATEMENT % on FY 2008 % on FY 2009 % on FY 2009 % on
(Amounts in thousands of euros) FY 2008 Value of One Time Value of Projectio Value of One Time Value of
Prod. Restart Prod. n Prod. Restart Prod.
Revenues from Private Label Mix 0 0% 893 12.9%
Revenues from Juice in Drums 3,856 61% 5,977 86.4%
Revenues from D-Limonene / Oils 406 6% 50 0.7%
NET REVENUES 4,261 67% 6,919 100.0%
Inventory Variation 2,089 33% 0 0%
VALUE OF PRODUCTION 6,351 100% 6,919 100%
COGS -5,311 -84% -2,473 -39% (5,806) -84% (1,092) -16%
GROSS MARGIN 1,040 16% -2,473 -39% 1,113 16% -1,092 -16%
S, G&A -1,482 -23% -65 -1% (1,569) -23% (38) -1%
EBITDA -442 -7% -2,538 -40% -457 -7% -1,130 -16%
Total Amortization -2,758 -43% (1,970) -28%
OPERATING INCOME (EBIT) -3,200 -50% -2,538 -40% -2,427 -35% -1,130 -16%
Interest Expense -269 -4% (387) -6%
Extraordinary Income (less Extr Charges) -22 0% 150 2%
NET INCOME BEFORE TAXES -3,491 -55% -2,538 -40% -2,664 -39% -1,130 -16%
Taxes -65 -1% (62) -1%
NET INCOME (LOSS) -3,556 -56% -2,538 -40% -2,727 -39% -1,130 -16%

21. Agenda
1. Company Overview
2. Investment Opportunity
3. History
4. 4 Year Projections
Feedback: Giuseppe Mascarella
giuseppe@viovijuice.com
Cell: +1 425 269 5478
13/01/2008 CONFIDENTIAL 21

22. Break Even in 2010
Net Revenues COGS Other Costs One Time Restart Net Profit (Loss)
25,000 Net Profit (Without Amortization & One Time Restart Costs)
6,000 4,338 4,937
3,565
20,000 4,000 2,664
Thousands of Euros
Thousands of Euros
2,000
15,000 -756 2,285
-797
0 1,119
583
10,000 -2,000 -659
-4,000
5,000 -3,857
-6,000
-6,094
0 -8,000
FY 2008 FY 2009 FY 2010 FY 2011 FY 2012 FY 2013 FY 2008 FY 2009 FY 2010 FY 2011 FY 2012 FY 2013
FY 2008 FY 2009 FY 2010 FY 2011 FY 2012 FY 2013
% % % % % %
(€ / 1.000) (€ / 1.000) (€ / 1.000) (€ / 1.000) (€ / 1.000) (€ / 1.000)
Net Revenues 4.261 67,1% 6.919 100,0% 17.330 100,0% 18.781 100,0% 20.526 100,0% 22.231 100,0%
Inventory Variation 2.089 32,9% 0 0,0% 0 0,0% 0 0,0% 0 0,0% 0 0,0%
Gross Profit 6.351 100,0% 6.919 100,0% 17.330 100,0% 18.781 100,0% 20.526 100,0% 22.231 100,0%
COGS 5.311 83,6% 5.806 83,9% 12.315 71,1% 12.822 68,3% 13.769 67,1% 14.881 66,9%
Admin. & Mktg 1.482 23,3% 1.569 22,7% 1.724 9,9% 1.771 9,4% 1.848 9,0% 1.892 8,5%
Interest Expense 269 4,2% 387 5,6% 458 2,6% 413 2,2% 340 1,7% 243 1,1%
Taxes & Others 86 1,4% -88 -1,3% 169 1,0% 210 1,1% 230 1,1% 278 1,2%
Amortization 2.758 43,4% 1.970 28,5% 3.323 19,2% 2.982 15,9% 3.220 15,7% 2.652 11,9%
One Time Restart 2.538 40,0% 1.130 16,3% 0 0,0% 0 0,0% 0 0,0% 0 0,0%
Net Profit (Loss) -6.094 -96,0% -3.857 -55,7% -659 -3,8% 583 3,1% 1.119 5,4% 2.285 10,3%
Net Profit (Without
Amortization & One -797 -12,6% -756 -10,9% 2.664 15,4% 3.565 19,0% 4.338 21,1% 4.937 22,2%
Time Restart Costs)

23. (Thousands of Euros) EBITDA EBIT Net Profit Cash Flow
FY 2008 -442 -3.200 -3.556
FY 2009 -457 -2.427 -2.727
FY 2010 3.291 -32 -659 739
FY 2011 4.188 1.205 583 1.287
FY 2012 4.909 1.689 1.119 1.834
FY 2013 5.458 2.806 2.285 2.277
6,000
5,000
4,000
3,000
Thousands of euros
2,000 EBITDA
1,000 EBIT
0 Net Profit
-1,000
Cash Flow
-2,000
-3,000
-4,000
FY 2009 FY 2010 FY 2011 FY 2012 FY 2013